Kailera Therapeutics KLRA Growth Metrics (2025-2026)

NASDAQ KLRA
$13.27 +0.06 (+0.45%)
At close: Nov 13, 2026 · 4:00 PM EST
Reported Financials

Kailera Therapeutics Quarterly Growth Metrics

Periods 7 quarters
Latest Sep 2026

Kailera Therapeutics reported revenue growth of -371.39% for the quarter ended Sep 2026. These growth metrics cover 7 quarters of results from Mar 2025 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

1Y3Y5Y7Y10YAll
Download Data
Growth MetricsGrowth Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Growth Ratios
Share-based Compensation (QoQ)Stock Comp. (QoQ) 7.09%161.74%-17.62%12.00%111.83%18.90%
Share-based Compensation Growth (1y)Stock Comp. Growth (1y) 158.63%411.59%132.40%
Revenue (QoQ) -226.93%-5.88%-274.84%-6.17%
Revenue Growth (1y) 241.25%-370.08%-371.39%
Return on Sales [ROS] Growth (1y)ROS Growth (1y) -0.03M
Return on Equity [ROE] (QoQ)ROE (QoQ) 0.01M
Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ) -68.00319.00
Return on Assets [ROA] (QoQ)ROA (QoQ) -7.00132.00
Property, Plant & Equipment (Net) (QoQ)PP&E (Net) (QoQ) -5.17%-5.45%-5.76%
Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) 835.41%
Operating Margin Growth (1y) -0.03M
Operating Income (QoQ)Op. Inc (QoQ) -49.82%-30.86%-67.35%-26.13%-43.37%12.39%
Operating Income Growth (1y)Op. Inc Growth (1y) -313.82%-295.98%-165.12%
Net Margin Growth (1y) -0.03M
Net Income towards Common Stockholders (QoQ)Net Income (QoQ) -60.97%-36.88%-57.49%-26.38%-41.14%14.05%
Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) -338.55%-284.52%-141.44%
Net Income (QoQ) -60.97%-36.88%-57.49%-26.38%-41.14%14.05%
Net Income Growth (1y) -338.55%-284.52%-141.44%
Net Cash Flow (QoQ)NCF (QoQ) 99.45%-758.31%1,902.63%-177.69%138.14%-228.63%
Net Cash Flow Growth (1y)NCF Growth (1y) 33.31%4,684.37%-587.02%
Income After Tax (QoQ) -51.87%-32.72%-64.11%-27.07%-41.09%14.05%
Income After Tax Growth (1y) -320.29%-290.46%-152.85%
Free Cash Flow (QoQ)FCF (QoQ) -44.12%-13.22%-46.64%-56.86%-13.49%-72.41%
Free Cash Flow Growth (1y)FCF Growth (1y) -275.31%-195.55%-350.09%
FCF Margin Growth (1y) -0.01M
EPS (Diluted) (QoQ) -60.97%-36.88%-57.49%99.99%99.97%32.23%
EPS (Diluted) Growth (1y) 99.98%100.00%100.00%
EPS (Basic) (QoQ) -60.97%-36.88%-57.49%99.99%99.97%32.23%
EPS (Basic) Growth (1y) 99.98%100.00%100.00%
EBT (QoQ) -51.87%-32.72%-64.11%-27.07%-41.09%14.05%
EBT Margin Growth (1y) -0.03M
EBT Growth (1y) -320.29%-290.46%-152.85%
EBIT (QoQ) -49.82%-30.86%-67.35%-26.13%-43.37%12.39%
EBIT Margin Growth (1y) -0.03M
EBIT Growth (1y) -313.82%-295.98%-165.12%
EBITDA Margin Growth (1y) -0.03M
Cash from Operations (QoQ)Cash from Ops. (QoQ) -44.12%-13.22%-55.16%-48.24%-13.49%-72.41%
Cash from Operations Growth (1y)Cash from Ops. Growth (1y) -275.31%-195.55%-350.09%
Cash from Investing Activities (QoQ)Cash from Investing (QoQ) -36.25%135.70%-1,574.47%105.85%-2,599.12%119.41%
Cash from Investing Activities Growth (1y)Cash from Investing Growth (1y) 141.97%-669.86%318.50%
Cash & Equivalents (QoQ)Cash & Equiv. (QoQ) -41.90%-0.40%-3.41%63.68%-30.23%16.52%-18.24%
Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) -8.51%9.87%28.54%8.81%
Assets (QoQ) -9.76%93.90%-10.67%
Assets Growth (1y) 287.96%

Kailera Therapeutics Growth Metrics API

Pull Kailera Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key. 

https://data.businessquant.com/statements?ticker=KLRA&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY
API documentation